人黑色素瘤细胞MeWo

细胞名称

人黑色素瘤细胞MeWo

货物编码

BFN60810339

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研   3类

培养体系

90%DMEM+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人黑色素瘤细胞MeWo取自78岁男性，该细胞源于ECACC

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ERK genetic alteration cell panel (ATCC TCP-1033).

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Doubling time: ~32 hours (PBCF).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: HLA class I peptidome analysis by proteomics.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突变

Homozygous for CDKN2A p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu; c.280_281CC>TT) (PubMed=17260012; PubMed=23851445; ATCC).

FGFR1 p.Pro252Ser (c.754C>T) (PubMed=23851445).

Heterozygous for MAPK3 p.Pro246Ser (c.736C>T) (ATCC).

TP53 p.Gln317Ter (c.949C>T) (PubMed=17260012; PubMed=23851445).

HLA信息

Class I

HLA-A        A*02:01,26:01

HLA-B        B*14:02,38:01

HLA-C        C*08:02,12:03

Class II

HLA-DP        DPB1*04:01,04:02

HLA-DQ        DQB1*03:01:01,05:01

HLA-DR        DRB1*11:01,01:02

STR信息

Amelogenin        X,Y

CSF1PO        12 (ATCC; CLS; Cosmic-CLP; JCRB; PubMed=25877200)

10,12 (ESTDAB)

D3S1358        17

D5S818        12,13

D7S820        10,12

D8S1179        13,15

D13S317        8 (Cosmic-CLP; ESTDAB)

8,9 (ATCC; CLS; JCRB; PubMed=25877200)

D16S539        10,12

D18S51        14,17

D21S11        30,32.2

FGA        22

Penta D        10

Penta E        5 (CLS)

5,15 (PubMed=25877200)

TH01        7,9

TPOX        8,10 (ATCC; CLS; Cosmic-CLP; JCRB; PubMed=25877200)

9,11 (ESTDAB)

vWA        15

参考文献

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)